Attention is focused on whether the SGLT-2 inhibitor Jardiance can settle as a reimbursed prescription option for chronic kidney disease in the second half of the year.

According to industry sources, the Health Insurance Review and Assessment Service is currently reviewing the reimbursement expansion of Boehringer Ingelheim and Lilly Korea’s Jardiance (empagliflozin). After the pharmaceutical companies submitted their applications in the first half of the year, HIRA began discussions in earnest after collecting expert opinions from relevant academic societies.

The drug is for reducing the risk of progression of kidney disease or death from cardiovascular disease, regardless of the prese